Silverback Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 92

Employees

  • Latest Deal Type
  • Debt

  • Financing Rounds
  • 8

  • Investments
  • 1

Silverback Therapeutics General Information

Description

Developer of an immune technology platform designed to offer systemically delivered, tissue-targeted therapeutics. The company is focused on leveraging its technology platform to develop tissue targeted therapeutics, enabling users to treat cancer, chronic viral infections, and other serious diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 500 Fairview Avenue North
  • Suite 600
  • Seattle, WA 98109
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Former Stock Listing
SBTX
Corporate Office
  • 500 Fairview Avenue North
  • Suite 600
  • Seattle, WA 98109
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Silverback Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Silverback Therapeutics‘s full profile, request access.

Request a free trial

Silverback Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an immune technology platform designed to offer systemically delivered, tissue-targeted therapeutics. The c
Biotechnology
Seattle, WA
92 As of 2022

South San Francisco, CA
 

Framingham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Silverback Therapeutics Competitors (48)

One of Silverback Therapeutics’s 48 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Xenetic Biosciences Corporation Framingham, MA
CSL Behring Corporation King Of Prussia, PA
Cantex Pharmaceuticals Formerly VC-backed Weston, FL
Oncorus Formerly VC-backed Andover, MA
You’re viewing 5 of 48 competitors. Get the full list »

Silverback Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Silverback Therapeutics Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Silverback Therapeutics‘s full profile, request access.

Request a free trial

Silverback Therapeutics Acquisitions (1)

Silverback Therapeutics’s most recent deal was a Reverse Merger with ARS Pharmaceuticals for . The deal was made on 08-Nov-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ARS Pharmaceuticals 08-Nov-2022 Reverse Merger Pharmaceuticals
To view Silverback Therapeutics’s complete acquisitions history, request access »

Silverback Therapeutics FAQs

  • When was Silverback Therapeutics founded?

    Silverback Therapeutics was founded in 2016.

  • Where is Silverback Therapeutics headquartered?

    Silverback Therapeutics is headquartered in Seattle, WA.

  • What is the size of Silverback Therapeutics?

    Silverback Therapeutics has 92 total employees.

  • What industry is Silverback Therapeutics in?

    Silverback Therapeutics’s primary industry is Biotechnology.

  • Is Silverback Therapeutics a private or public company?

    Silverback Therapeutics is a Private company.

  • What is Silverback Therapeutics’s current revenue?

    The current revenue for Silverback Therapeutics is .

  • How much funding has Silverback Therapeutics raised over time?

    Silverback Therapeutics has raised $6M.

  • Who are Silverback Therapeutics’s investors?

    Alexandria Real Estate Equities, Altamont Pharmaceutical Holdings, Boxer Capital, Bristol-Myers Squibb, and Celgene are 5 of 18 investors who have invested in Silverback Therapeutics.

  • Who are Silverback Therapeutics’s competitors?

    CytomX Therapeutics, Xenetic Biosciences, CSL Behring, Cantex Pharmaceuticals, and Oncorus are some of the 48 competitors of Silverback Therapeutics.

  • When was Silverback Therapeutics acquired?

    Silverback Therapeutics was acquired on 26-Mar-2025.

  • Who acquired Silverback Therapeutics?

    Silverback Therapeutics was acquired by ARS Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process